NUDGE-EHR Replication Trial at Mass General Brigham

NACompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

March 15, 2024

Study Completion Date

June 15, 2024

Conditions
AgingBenzodiazepine Sedative Adverse ReactionAnticholinergic Adverse ReactionAdverse Drug Event
Interventions
OTHER

Follow-up booster Alert

Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered

OTHER

Pre-commitment

A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.

OTHER

Enhanced Alert

An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.

Trial Locations (1)

02114

Mass General Brigham, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Brigham and Women's Hospital

OTHER